企業概要
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical enterprise dedicated to developing therapeutic solutions for patients suffering from debilitating central nervous system disorders. The company functions within the broader healthcare sector and specifically within the biotechnology industry, a field characterized by significant research and development cycles aimed at addressing unmet medical needs. As of the latest reporting data, the company maintains a market capitalization of $1.33B and employs 133 individuals to support its clinical operations and product development efforts. Although the annual revenue is not disclosed in the available data, the market cap of $1.33B indicates that the market values the company's potential in the central nervous system space at a substantial level, suggesting significant investor interest in its pipeline assets.
財務健全性
The company reports a net income of $-161,152,000 for the trailing twelve months, while EBITDA stands at $-168,504,992, highlighting a substantial operational loss. The gap between the reported revenue, which is listed as unavailable, and the significant net income loss reveals a cost structure heavily weighted towards research, development, and clinical trial expenses typical of clinical-stage biotechnology firms. Free cash flow is reported at $-83,129,872, indicating that the company is currently burning cash, which limits immediate financial flexibility and necessitates reliance on external capital sources or existing reserves to fund operations. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure that reflects the accounting treatment of R&D expenditures and the lack of commercial profitability at this stage of development. On the balance sheet, the company holds $305.10M in cash against a debt load of $5.80M, resulting in a debt-to-equity ratio of 1.27. While the cash position provides a buffer, the debt-to-equity ratio suggests a capital structure that is not purely conservative, as the company carries measurable leverage relative to its equity base. The current ratio is an exceptionally high 20.01, indicating that the company possesses a robust liquidity position with current assets vastly exceeding its current liabilities, ensuring short-term solvency. Return on equity is negative at -56.2% and return on assets is negative at -34.3%, metrics that reveal that management is currently utilizing shareholder capital and assets to generate losses rather than profits, a common characteristic for early-stage biotech companies before product commercialization.
バリュエーション評価
The trailing twelve-month P/E ratio is unavailable due to negative earnings, whereas the forward P/E is listed as -7.87, implying that the market prices in future earnings recovery based on anticipated clinical milestones or sales. The price-to-book ratio stands at 2.82, indicating that the market values the company's equity at a premium of roughly 182% over its book value, reflecting the intangible value of its intellectual property and pipeline. The price-to-sales ratio is unavailable, and the EV/EBITDA multiple is -5.91, suggesting that traditional valuation multiples are distorted by the company's negative earnings and cash flow, necessitating a focus on pipeline potential rather than current profitability. The stock has traded between a 52-week low of $12.24 and a 52-week high of $29.50, with the current trading price situated at a specific point within this range relative to historical volatility. The beta value is unavailable in the provided data, which limits the ability to quantify the company's price volatility relative to the broader market index, though the wide trading range suggests inherent high risk.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both unavailable in the current dataset, preventing a direct comparison of how quickly earnings are expanding relative to top-line sales. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, indicating that all available earnings and cash flow are being retained and reinvested into research, development, and clinical trials to accelerate product growth. The overall growth and income profile is defined by a lack of current income generation, with the company's value entirely dependent on the successful advancement of its product candidates through clinical stages. This reinvestment strategy is standard for clinical-stage biopharmaceutical companies, where capital expenditure is prioritized over shareholder distributions until commercial revenue is generated.